Evolving Strategies for the Management of Obstructive Hypertrophic Cardiomyopathy.
J Card Fail
; 30(9): 1136-1153, 2024 Sep.
Article
en En
| MEDLINE
| ID: mdl-38777216
ABSTRACT
For many years, treatment of hypertrophic cardiomyopathy (HCM) has focused on non-disease-specific therapies. Cardiac myosin modulators (ie, mavacamten and aficamten) reduce the pathologic actin-myosin interactions that are characteristic of HCM, leading to improved cardiac energetics and reduction in hypercontractility. Several recently published randomized clinical trials have demonstrated that mavacamten improves exercise capacity, left ventricular outflow tract obstruction and symptoms in patients with obstructive HCM and may delay the need for septal-reduction therapy. Long-term data in real-world populations will be needed to fully assess the safety and efficacy of mavacamten. Importantly, HCM is a complex and heterogeneous disease, and not all patients will respond to mavacamten; therefore, careful patient selection and shared decision making will be necessary in guiding the use of mavacamten in obstructive HCM.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Cardiomiopatía Hipertrófica
/
Manejo de la Enfermedad
Límite:
Humans
Idioma:
En
Revista:
J Card Fail
/
J. card. fail
/
Journal of cardiac failure
Asunto de la revista:
CARDIOLOGIA
Año:
2024
Tipo del documento:
Article